Category:

Press Releases

• • •

• • •

Zenas BioPharma Announces Publication of Phase 2 Study of Obexelimab, an Investigational Treatment for IgG4-Related Disease (IgG4-RD), in The Lancet Rheumatology

Study found obexelimab produced rapid, strong, and sustained clinical improvement, including complete clinical remission, in most patients with active IgG4-RD Results support the continued development of obexelimab for the treatment of IgG4-RD and potentially other B cell-mediated autoimmune conditions WALTHAM, Mass., Aug. 01, 2023 (GLOBE NEWSWIRE) — Zenas BioPharma, a

• • • Read More • • •

Conagen and Sumitomo Chemical jointly develop a new era of renewable carbon materials

Bedford, Mass., Aug. 01, 2023 (GLOBE NEWSWIRE) — Conagen, the bioplatform innovator and biomanufacturer, and Sumitomo Chemical, Japan’s leading chemical company, have announced to jointly develop p-hydroxystyrene (HS) and its polymer, poly p-hydroxystyrene (PHS), using a combination of biosynthesis, chemosynthesis, and polymerization. The monomer and the polymer are 100% renewable

• • • Read More • • •

ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Atlas Lithium Corporation f/k/a Brazil Minerals, Inc. Investors with Losses to Secure Counsel Before Important August 1 Deadline in Securities Class Action – ATLX, BMIX

NEW YORK, July 29, 2023 (GLOBE NEWSWIRE) — WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Atlas Lithium Corporation f/k/a Brazil Minerals, Inc. (NASDAQ: ATLX, BMIX) between March 25, 2022 and May 3, 2023, both dates inclusive (the “Class Period”), of the important

• • • Read More • • •

S DEADLINE: ROSEN, A LEADING LAW FIRM, Encourages SentinelOne, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action – S

NEW YORK, July 29, 2023 (GLOBE NEWSWIRE) — WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of SentinelOne, Inc. (NYSE: S) between June 1, 2022 and June 1, 2023, both dates inclusive (the “Class Period”), of the important August 7, 2023 lead plaintiff deadline.

• • • Read More • • •

RECENT POSTS